Literature DB >> 8970370

Effect of the beta-agonist clenbuterol on dexamethasone-induced diaphragm dysfunction in rabbits.

T X Jiang1, A Cairns, J D Road, P G Wilcox.   

Abstract

The present study was designed to examine whether clenbuterol (CLEN) could reduce dexamethasone (DEX)-induced diaphragm dysfunction. We studied four groups of New Zealand white (NZW) rabbits, each receiving one of the following daily injections subcutaneously for 2 wk: saline (control), DEX 3 mg/kg, DEX 3 mg/kg + CLEN 2 mg/kg, and CLEN 2 mg/kg. Diaphragm fiber cross-sectional areas (CSA) were measured. Twitch transdiaphragmatic pressure (Pdi) and tetanic Pdi were measured during bilateral phrenic stimulation both before and after 60 min of inspiratory resistive loading (IRL). DEX produced a marked atrophy of type IIa and type IIb diaphragm fibers. This diaphragm atrophy was prevented by CLEN in the DEX plus CLEN group. CLEN alone increased CSAs of all three types of diaphragm fibers. Significant reductions in twitch Pdi and tetanic Pdi at all stimulation frequencies both before and after IRL were observed similarly in the DEX group as well as in the DEX plus CLEN group compared with the control animals. We conclude that DEX produces significant diaphragm atrophy and decreases diaphragmatic contractility. CLEN produces hypertrophy of the diaphragm and minimizes diaphragm atrophy induced by DEX, but it has no demonstrable protective effect on DEX-induced diaphragm dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970370     DOI: 10.1164/ajrccm.154.6.8970370

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  2 in total

1.  Protective Effects of Clenbuterol against Dexamethasone-Induced Masseter Muscle Atrophy and Myosin Heavy Chain Transition.

Authors:  Daisuke Umeki; Yoshiki Ohnuki; Yasumasa Mototani; Kouichi Shiozawa; Kenji Suita; Takayuki Fujita; Yoshiki Nakamura; Yasutake Saeki; Satoshi Okumura
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

2.  Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol.

Authors:  Yoshiki Ohnuki; Daisuke Umeki; Yasumasa Mototani; Kouichi Shiozawa; Megumi Nariyama; Aiko Ito; Naoya Kawamura; Yuka Yagisawa; Huiling Jin; Wenqian Cai; Kenji Suita; Yasutake Saeki; Takayuki Fujita; Yoshihiro Ishikawa; Satoshi Okumura
Journal:  Physiol Rep       Date:  2016-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.